Studying Biomarkers in Samples From Younger Patients With Wilms Tumor

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

2227 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RATIONALE: Studying samples of blood, tissue, or bone marrow from patients with cancer in the laboratory may help doctors to learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This research trial studies biomarkers in samples from younger patients with Wilms tumor.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Biomarkers in Tumor Tissue Samples From Young Patients With Very Low Risk Wilms Tumors

NCT01004783

Kidney Cancer

COMPLETED

Biomarkers in Blood and Tumor Tissue Samples From Patients With Wilms Tumor

NCT01314391

Kidney Cancer Renal Failure

COMPLETED

Studying Biomarkers in Samples From Younger Patients With Wilms Tumor

NCT01542333

Kidney Cancer

COMPLETED

Studying Biomarkers in Urine Samples From Younger Patients With Wilms Tumor

NCT01614808

Recurrent Wilms Tumor and Other Childhood Kidney Tumors Stage III Wilms Tumor

COMPLETED

Studying Genes Using Cord Blood and Placenta Samples From Relatively Healthy Newborns and Samples From Younger Patients With Wilms Tumor

NCT01576211

Kidney Cancer

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OBJECTIVES:

* To analyze 250 favorable-histology Wilms tumor (FHWT) samples from patients registered on NWTS4 for gain of 1q and 15q, and loss of 1p, 16q, 17p, and 22q by subtelomeric multiplex ligation-dependent probe amplification (MLPA), and to determine their association with relapse-free and overall survival.
* To develop a robust multiplex MLPA test using multiple synthesized probes to those targets identified as significantly associated with relapse in Aim 1.
* To validate the multiplex MLPA test designed and tested in Aim 2 on an independent set of 1727 FHWT and 250 anaplastic WT registered on NWTS-5.

OUTLINE: Archived DNA samples are analyzed for gain of 1q and 15q, and loss of 1p, 16q, 17p, and 22q by MLPA. Assay results are then researched for accuracy, clinical validity, sensitivity, precision, and potential analytical interferences.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Kidney Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

DNA analysis

Intervention Type GENETIC

nucleic acid amplification

Intervention Type GENETIC

diagnostic laboratory biomarker analysis

Intervention Type OTHER

medical chart review

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

DISEASE CHARACTERISTICS:

* DNA samples from FHWT patients registered on:

* NWTS-4
* NWTS-5 with focal and diffuse anaplasia tumors

PATIENT CHARACTERISTICS:

* Not specified

PRIOR CONCURRENT THERAPY:

* Not specified

Maximum Eligible Age

120 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No